European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 20 October 2026 - 15:52

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Darunavir Viatris (previously Darunavir Mylan), darunavir, Date of authorisation: 03/01/2017, Revision: 19, Status: Authorised

Submitted by Anonymous (not verified) on 20 October 2026 - 15:36

Human medicines European public assessment report (EPAR): Darunavir Viatris (previously Darunavir Mylan), darunavir, Date of authorisation: 03/01/2017, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Deferasirox Accord, deferasirox, Date of authorisation: 09/01/2020, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 20 October 2026 - 15:35

Human medicines European public assessment report (EPAR): Deferasirox Accord, deferasirox, Date of authorisation: 09/01/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Tosmova (previously Tocilizumab STADA and Tofidence), tocilizumab, Date of authorisation: 20/06/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 20 October 2026 - 15:30

Human medicines European public assessment report (EPAR): Tosmova (previously Tocilizumab STADA and Tofidence), tocilizumab, Date of authorisation: 20/06/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 20 October 2026 - 15:15

Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 20 October 2026 - 14:36

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 13, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More